C3 gene linked to AMD

Article

The gene, complement C3, has been identified as playing an important role in the pathogenesis of age-related macular degeneration.

The gene, complement C3, has been identified as playing an important role in the pathogenesis of age-related macular degeneration (AMD), according to a study published in the August issue of the New England Journal of Medicine.

John R.W. Yates and colleagues from the Genetic Factors in AMD Study Group, tested for an association between AMD and 13 single-nucleotide polymorphisms (SNPs) spanning the complement genes C3 and C5 in case subjects and control subjects from the South East region of England. Each subject was examined by an ophthalmologist and had independent grading of fundus photographs to confirm their disease status. To test for replication of the most significant findings, Scottish cases and controls were genotyped.

It was discovered that the common functional polymorphism rs2230199 in the C3 gene, corresponding to the electrophoretic variants C3S (slow) and C3F (fast), was strongly associated with AMD in both the English group (603 cases and 350 controls; p=5.9x10-5) and the Scottish group (244 cases and 251 controls; p=5.0x10-5).

It would appear, from these findings, that the complement C3 gene might play a role in the pathogenesis of AMD.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.